Cell reports. Medicine · 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.
Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boucau Julie, Chew Kara W, Choudhary Manish C, Deo Rinki, Regan James, Flynn James P, Crain Charles R, Hughes Michael D, Ritz Justin, Moser Carlee, Dragavon Joan A, Javan Arzhang C, Nirula Ajay, Klekotka Paul, Greninger Alexander L, Coombs Robert W, Fischer William A, Daar Eric S, Wohl David A, Eron Joseph J, Currier Judith S, Smith Davey M, POSITIVES study team, Li Jonathan Z, Barczak Amy K, ACTIV-2/A5401 Study Team
Аннотация
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) are among the treatments recommended for high-risk ambulatory persons with coronavirus 2019 (COVID-19). Here, we study viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlanivimab in the ACTIV-2 trial (ClinicalTrials.gov: NCT04518410). Viral load by qPCR and viral culture are performed from anterior nasal swabs collected on study days 0 (day of treatment), 1, 2, 3, and 7. Treatment with mAbs results in rapid clearance of culturable virus. One day after treatment, 0 of 28 (0%) participants receiving mAbs and 16 of 39 (41%) receiving placebo still have culturable virus (p < 0.0001). Recrudescence of culturable virus is detected in three participants with emerging mAb resistance and viral RNA rebound. While further studies are necessary to fully define the relationship between shed culturable virus and transmission, these results raise the possibility that mAbs may offer immediate (household) and public-health benefits by reducing onward transmission.